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Abstract
Background: The mean 5–6-month survival after failed standard chemotherapy for metastatic colorectal cancer
(mCRC) necessitates more effective treatments for refractory mCRC. For untreated mCRC, S-1 + oral leucovorin (SL)
therapy offers promising results without severe toxicity. The ML18147 trial demonstrated that bevacizumab (Bev)
prolongs overall survival after mCRC progression. We conducted a single-centre phase-II trial to evaluate the safety
and efficacy of SL/Bev combination chemotherapy as mCRC salvage therapy.
Methods: Major eligibility criteria were confirmed adenocarcinoma diagnosis; age >20 years; Eastern Cooperative
Oncology Group performance status, 0–2; and progression after administration/intolerance of/to approved drugs for
mCRC. (5-FU, oxaliplatin, irinotecan, Bev, and anti-EGFR antibody, if KRAS wild-type). S-1 (80–120 mg/body) and
leucovorin (25 mg) were orally administered in a 1-week-on/1-week-off schedule. Bev (5 mg/kg) was administered
on day 1 of every 2-week cycle. The primary endpoint was disease control rate (DCR).
Results: A total of 31 patients were enrolled. DCR was 65 % [95 % confidence interval (CI), 48–100 %] and the
response rate was 7 % (95 % CI, 0.7–22 %). One patient showing partial response to SL/Bev had a BRAF-mutant
tumor. Median progression-free survival and overall survivals were 5.3 [95 % CI, 2.1–9.3] and 9.9 [95 % CI, 7.4–NA]
months, respectively. The most-frequent grade-3/4 adverse events were mucositis (26 %) and diarrhea (11 %), which
were manageable by dose reduction/interruption.
Conclusions: SL/Bev showed impressive activity in refractory mCRC and was tolerable, suggesting its potential as
an alternative chemotherapy for refractory mCRC.
Trial registration: This study has been registered in University Hospital Medical Information Network (UMIN)
Clinical Trials Registry (ID UMIN000009083) on 11 October 2012.
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Background
Systemic chemotherapy for metastatic colorectal cancer
(mCRC) has improved remarkably in recent years, cur-
rently allowing most mCRC patients to survive for >2 years.
Standard treatments for patients with mCRC include
chemotherapy regimens based on cytotoxic agents, such as
fluoropyrimidine, irinotecan, oxaliplatin and the vascular
endothelial growth factor (VEGF) antibody bevacizumab
(Bev), with the addition of epithelial growth factor receptor
(EGFR) antibodies cetuximab and panitumumab for RAS
wild-type patients [1, 2]. An additional file shows standard
therapies for metastatic colorectal cancer in the various
setting [see Additional file 1]. However, after failure of stand-
ard chemotherapy, the average survival rate is only 5–6
months. Therefore, there is a need for more effective treat-
ment for patients with refractory mCRC who maintain a
relatively good performance status (PS) and are willing to
receive further treatment.
S-1 (TS-1; Taiho Pharmaceutical Co. Ltd., Tokyo, Japan)
is an oral fluoropyrimidine anti-cancer agent that combines
tegafur as the effector drug with the 2 modulators gimeracil
and oteracil. Tegafur is a pro-drug of 5-fluorouracil (5-FU),
gimeracil is an inhibitor of dihydropyrimidine dehydrogen-
ase (DPD) which maintains the serum 5-FU level. Oteracil
inhibits the gastrointestinal toxicity of 5-FU. Several phase-
III trials on mCRC have demonstrated S-1 can be a substi-
tute for infusional 5-FU [3, 4]. Moreover, a phase-II study
demonstrated promising S-1 activity in heavily pre-treated
mCRC patients, including those treated with 5-FU [5].
Leucovorin (LV) is a well-known enhancer of 5-FU
activity by inhibiting thymidylate synthase (TS) [6].
Concomitant 5-FU+ LV therapy is used worldwide to treat
patients with mCRC as either first-line or adjuvant therapy.
In addition, oral tegafur/uracil (UFT) plus LV combination
therapy has demonstrated similar clinical efficacy to that of
intravenous 5-FU and LV, and it is associated with
improved convenience of care because an infusion pump
is not required [7]. On the other hand, little data is avail-
able on S-1 plus oral LV (SL) combination therapy.
Subsequently, Koizumi et al. conducted a phase-II study
of SL treatment in patients with previously untreated
mCRC, the results of which were promising [8]. On the
basis of these results, SL therapy is expected to yield high
anti-tumour activity compared with S1 monotherapy in
cases of refractory mCRC.
Bev is a humanized monoclonal antibody that inhibits
VEGF and has demonstrated activity both as first-line and
second-line therapy for mCRC in combination with fluoro-
pyrimidine with or without irinotecan or oxaliplatin [9–11].
However, the role of Bev in third-line or later-line therapy
of mCRC remains unclear. The continuation of Bev beyond
disease progression after first-line therapy has been demon-
strated to improve progression-free survival (PFS) and
overall survival (OS) in large phase-III trials [12, 13]. These
results suggest that Bev therapy after disease progression
may have a clinical benefit even in refractory patients
treated with Bev.
To test these hypotheses, we conducted a single-centre
phase-II trial to assess the efficacy and safety of SL + Bev
(SL/Bev) as a salvage therapy in patients with mCRC in
whom prior chemotherapy with 5-FU, oxaliplatin, irinote-
can, Bev and anti-EGFR antibodies has failed.
Methods
Patient eligibility
Major eligibility criteria were mCRC progression after
administration/intolerance of/to 5-fluouracil, oxaliplatin,
irinotecan and Bev, as well as anti-EGFR antibodies for
patient with KRAS wild-type tumours (KRAS mutational
status was detected in codons 12 and 13 using Cycleave
polymerase chain reaction technique). Other eligibility
criteria were as follows; age ≥20 years; histologically
confirmed adenocarcinoma of the colon/rectum; at least
1 measurable lesion according to Response Evaluation
Criteria in Solid Tumours (RECIST, version 1.1); Eastern
Cooperative Oncology Group (ECOG) Performance Status
(PS) 0–2 [14]; ability to take drugs orally; no prior S-1
therapy; adequate bone-marrow function (a neutrophil
count of ≥1500/mm3, a haemoglobin level of ≥8 g/dl, a
platelet count of ≥75,000/mm3), adequate liver function
(a serum total bilirubin level of ≤1.5 mg/dl, serum as-
partate aminotransferase and alanine aminotransferase
levels of ≤200 IU/l), and adequate renal function (a serum
creatinine level of ≤1.2 mg/dl and creatinine clearance
≥50 ml/min). Major exclusion criteria included prior sur-
gery, chemotherapy/radiotherapy within 2 weeks of enter-
ing the trial, uncontrolled comorbidities, active infection,
symptomatic brain metastases and severe ascites/pleural
effusion. The study protocol was approved by the ethics
review committee of Aichi Cancer Center Hospital and in-
formed consent was obtained before enrolment from all
patients. The study protocol was registered at the Univer-
sity Hospital Medical Information Network (UMIN) Clin-
ical Trials Registry (protocol ID UMIN000009083).
Study treatment
S-1 [80 mg/day for body surface area (BSA) <1.25 m2;
100 mg/day for 1.25 ≤ BSA < 1.50 m2; and 120 mg/day
for BSA ≥1.50 m2] and LV (50 mg/day, fixed dose) were
orally administered twice daily for 1 week followed by a
1-week rest. Bev (5 mg/kg) was administered as an intra-
venous infusion over 30 min on day 1 of every 2-week
cycle. If patients had no infusion reaction, the infusion
time was shortened to 15 min. In the event of grade-4
neutropenia or thrombocytopenia, grade-3 diarrhea or
stomatitis, and febrile neutropenia as well as depending
on the degree of toxicity in each patient, S-1 dose was
decreased by 1 level in the subsequent cycle. LV and Bev
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doses were not decreased. Treatments were continued until
disease progression, unacceptable toxicity, or withdrawal of
consent. The treatment was discontinued if treatment cycle
was delayed for >28 days or dose reduction was required
after a second step of reduction. Post-study anti-cancer
treatment was allowed on this protocol.
Assessments of efficacy and toxicity
Treatment response was evaluated in accordance with the
Response Evaluation Criteria in Solid Tumours (RECIST
version 1.1). The evaluation was performed at baseline
and every 8 weeks by computed tomography (CT). A
baseline CT scan was done within 4 weeks of starting
treatment. Best overall response was assessed by a blinded
review by an independent committee, which included two
radiologists. Response was not confirmed with repeat
scans in the study. The incidence and severity of adverse
events were graded using the National Cancer Institute
Common Toxicity Criteria version 4.0. Quality of life
(QOL) was assessed using EQ5D scores from a patient
report at baseline and every 2 weeks thereafter. EQ5D is a
standardised measure of the course of health processes. It
consists of 5 descriptive questions regarding dimensions
of morbidity, self-care, usual activities, pain/discomfort
and anxiety/depression. Each dimension has 3 levels of
response indicating the severity of a patient’s problems.
Study endpoints
The primary endpoint of this study was the disease control
rate [DCR: complete remission (CR) + partial remission
(PR) + stable disease (SD)], as assessed by the independent
review committee. The secondary endpoints were PFS, OS,
safety and QOL. The study was conducted according to the
intention-to-treatment principle (ITT). PFS and OS were
calculated as the time between the first day of treat-
ment and the day of proven disease progression or
death from any cause. Other causes of events without
disease progression were defined as censored. Survival
curves were estimated using the Kaplan-Meier method.
Statistical analyses were performed using R software
version 2.13.2 (R Project for Statistical Computing,
Vienna, Austria).
Statistical analyses
A one sample binomial design was used to determine the
sample size. The estimates were based on DCR of previ-
ous two trials comparing new drugs and best supportive
care (BSC). DCR in the trial of regorafenib and TAS102
were 41 and 43.8 %, while the DCR of BSC group in these
trials were 15 and 10.5 %, respectively [15, 16]. Therefore,
we hypothesised it would be beneficial if DCR was at least
44 % with this therapy, while under 22 % would be the
lower limit of interest. On the basis of this assumption,
the required sample size was calculated to be 28 patients
according to a null hypothesis of a DCR of ≤22 % versus
the alternative hypothesis of a DCR of >44 %, with 80 %
power and 0.05 alpha value (one-sided). Considering that
some patients may become ineligible after enrolment, the




Between October 2012 and November 2013, a total of
31 patients with mCRC were enrolled in this study at
the Aichi Cancer Center Hospital in Japan. Baseline
characteristics of the patients are summarized in Table 1.
The median age was 69 years (range 37–86 years, inter-
quartile range 61–73 years). Twenty-one patients were
male and 10 were female. Most patients had ECOG PS
of 0 or 1 (29 patients; 94 %). The primary site was the
colon in 25 patients (81 %) and rectum in 6 (19 %).
KRAS and BRAF mutations were present in 13 (37 %)
and two patients (7 %), respectively. Twenty-six patients
(84 %) had undergone primary tumour resections and 7
(22 %) had been treated with >4 lines of chemotherapy
prior to inclusion in the study.
Treatment results and efficacy
Three patients (9 %) were not eligible for assessments
because of an early termination of the treatment protocol: 2
because of disease progression and 1 because of sudden
death, possibly related to treatment. Of the 28 evaluated
patients, no patient achieved CR, two patients (7 %)
achieved PR, 18 patients (58 %) achieved SD and 8 patients
(26 %) showed PD, according to the independent review
committee. DCR was 65 % (95 % CI, 48–100 %) and the
overall response rate was 7 % (95 % CI, 0.7–22 %) by the
ITT analysis. The lower limit of one-sided confidence inter-
val of DCR (45 %) was higher than the predefined null
value (22 %); therefore, this study met its primary endpoint.
The highest percentage change from baseline in the sum of
the longest diameter of the target lesion, as assessed by the
central review committee, is shown in Fig. 1. During the
trial, 13 patients (42 %) showed some decrease in lesion size
compared with the baseline value. The median follow-up
period was 11.8 months (range 7.0–20.3 months, interquar-
tile range 9.6–18.2 months) as of June 2014. There were a
total of 28 patients with progression and 21 patients who
died whilst the median PFS and OS were 5.3 months (95 %
CI, 2.1–9.3 months; Fig. 2) and 9.9 months (95 % CI,
7.4 months- NA; Fig. 3), respectively. DCR was similar for
both KRAS-wild-type (61 %) and KRAS-mutant (69 %)
statuses, whereas both patients who achieved PR were
KRAS wild type. Among two patients with PR, one patient
had a BRAF-mutant tumour with multiple liver metastases
from an ascending colon cancer. The patient had primary
resistance to capecitabine + oxaliplatin + Bev combination
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therapy as first-line chemotherapy and irinotecan +
cetuximab combination therapy as second-line chemo-
therapy. This patient had a tumour reduction of 35 %
on day 50 and maintained the tumour response until
day 126. The patient’s serum tumor markers including
carcinoembryonic antigen (CEA) and carbohydrate
antigen 19–9 (CA19-9) levels decreased remarkably
during the protocol treatment. Median PFS in patients
with wild-type and mutant KRAS was 5.3 and 3.9 months,
and median OS was 10.9 and 9.5 months, respectively.
Drug delivery
The total number of treatment cycles administered was
299 and the median number of cycles administered was
nine (range 1–24, interquartile range 4–13). Dose reduc-
tion was required in 16 patients (52 %). The most com-
mon causes of dose reduction were grade-3 stomatitis or
diarrhea. The relative dose intensity to the planned dose
was 78 % for S-1 and LV and 87 % for Bev. Currently,
three patients (9 %) remain on the protocol therapy.
Twenty-eight patients discontinued treatment: 26 (84 %)
because of disease progression and 2 (7 %) because of
adverse events. Reasons for discontinuation due to adverse
events included infection and sudden death. Sixteen
patients have received treatment after the study, including
14 patients being treated with regorafenib, six patients
with re-introduction chemotherapy and one patient with a
new investigational drug.
Toxicity and QOL
Toxicity data are summarized in Table 2. Non-hematological
toxicities were more common than hematological toxicities.
The most common non-hematological toxicities of any grade
were stomatitis (74 %), fatigue (74 %), anorexia (68 %) and
diarrhea (48 %). The most common grade-3/4 non-
hematological toxicity was stomatitis (26 %) and diarrhea
(10 %). Eight patients experienced grade-3 stomatitis,
which occurred in the first treatment cycle in six patients
and in the fourth cycle in two patients. However, this tox-
icity was reversible with either appropriate treatment,
interruption or dose reduction. No patients required hos-
pitalisation and had to terminate the protocol treatment
for this reason. Diarrhea was easily managed by using
anti-diarrheal drugs and was more responsive than we ex-
pected. No grade-4 adverse events of non-hematological
toxicity were observed. Hematological toxicities were gen-
erally mild and grade-3/4 hematological toxicities were
rare. There was a single case of treatment-related death; a
70-year-old male with multiple lung metastases suddenly
died on day 9 of the fourth cycle. The cause of death was
most likely because of cardiorespiratory failure but was
not definitively determined. For QOL, overall mean
mobility, self-care, usual activities, pain/discomfort and


















No of metastatic site,
1 10 (32)
2 9 (29)














Number of lines prior therapy
2 8 (19)
3 16 (59)
≥ 4 7 (22)
Median CEA level ng/ml (range, interquartile range) 116 (0–42,230,
31–350)
Median CA19-9 level ng/ml (range, interquartile range) 222 (5–9820,
38–965)
ECOG Eastern Cooperative Oncology Group, CEA serum carcinoembryonic
antigen, CA19-9 carbohydrate antigen 19–9
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anxiety/depression subscale scores remained stable
from before treatment to after treatment.
Discussion
In this study, first, we demonstrated SL/Bev has significant
clinical activity, yielding 58 % disease stabilisation. This,
together with 7 % partial response, resulted in 65 % DCR
in heavily pre-treated mCRC. This trial met the pre-
specified primary endpoint and also achieved favourable
median PFS and OS of 5.3 and 9.9 months, respectively.
Furthermore, SL/Bev was generally tolerated and appears
to have little impact on QOL.
Several prospective studies have evaluated various cyto-
toxic and/or targeted agents in the setting of refractory
mCRC, and potent new anti-cancer agents have been devel-
oped in recent years. The results of large phase-III study of
regorafenib, oral multi-kinase inhibitor, showed prolonged
survival compared with a placebo in patients with heavily
pre-treated mCRC, with a DCR of 41 %, median PFS of
1.9 months and median OS of 6.4 months [15]. In addition,
TAS-102 reported encouraging results compared with
placebo in randomized phase-III study, which is a new oral
nucleoside anti-tumour agent consisting of trifluorothymi-
dine and a thymidine phosphorylase inhibitor [17]. The
results showed a DCR of 44.0 %, median time PFS of
Fig. 1 Waterfall plots of best overall percent change from baseline in sum of target lesion diameters. Evaluation was assessed by the central
review committee. (evaluable patients only, n = 28). Abbreviations; PR, partial response; SD, stable disease; PD, progressive disease
Fig. 2 Kaplan–Meier survival curve for progression free survival (PFS)
in the intention to treat (ITT) population (n = 31). The median PFS
was 5.3 months (95 % CI, 2.1–9.3)
Fig. 3 Kaplan-Meier survival curve for overall survival (OS) in the
intention to treat (ITT) population (n = 31). The median OS was
9.9 months (95 % CI, 7.4-NA)
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2.0 months and median OS of 7.1 months. Compared with
the results of previous studies, the present study’s DCR of
65 % for refractory patients was higher and the median OS
of 9.9 months was longer. Although, the favourable OS was
partly due to post-study anti-cancer treatment; approxi-
mately half of the failures (16 of 28) underwent further
treatment after stopping protocol therapy. Indeed, a PFS
of 5.3 months is much better than that reported previously
in salvage settings. Moreover, two patients achieved PR
despite resistance to several chemotherapies. These results
indicate SL/Bev has individual anti-cancer activity in this
heavily pre-treated population.
In this study, SL/Bev showed an acceptable toxicity, con-
sidering that it was previously a heavily treated population.
The most common adverse events in our study were non-
hematological toxicities such as stomatitis and diarrhea.
Grade-3/4 stomatitis reported in this study was 26 %, which
is higher than that in a previous study for this schedule in
patients with untreated mCRC, where stomatitis was
reported in only 8.3 % patients [18]. This discrepancy may
be ascribed to the fact that patients included in the current
study were more heavily treated. Although dose modifica-
tion was required in 16 of the 31 patients because of muco-
sitis, no discontinuation for this reason was reported,
suggesting that mucositis was generally manageable with
dose reduction/interruption. Adverse events potentially
associated with Bev were well tolerated. Although epistaxis
and hypertension were relatively frequent, both symptoms
were ≤ grade 2. Moreover, serious adverse events, such as
thrombosis and bowel perforation, were not observed. The
safety of Bev addition appears to be high. However, it
should be noted that one patient died of sudden death
possibly related to therapy; this illustrates the need for more
caution when treating such a fragile patient population.
The rationale for this combination therapy was based
on prior success with S-1 monotherapy against refractory
mCRC and the synergistic effects of LV + Bev combination
therapy. In a phase-II study, S-1 monotherapy showed
promising activity in heavily pre-treated patients with
mCRC who had previously failed a regimen containing
irinotecan and oxaliplatin. A DCR of 42.9 %, median PFS
of 3–4 months and a median OS of 10–13 months were
achieved, which suggest that S-1 has potent tumor activity
even in 5-FU-refractory mCRC [5]. Several preclinical re-
ports have presented evidence to support the effectiveness
of S-1. For example, S-1 showed higher tumor growth
inhibition than UFT did in an orthotopic implantation
model of colon cancer, and it promoted anti-tumor activ-
ity in 5-FU-resistant cancer cell lines [19]. In addition, it
has been suggested that DPD inhibition plays a significant
role of S-1 in chemo-resistant cancer cells. According to
the results of the randomized phase-II/III study, which
verify the non-inferiority of IRIS regimen (irinotecan + S-
1) to FOLFIRI regimen (fluorouracil + LV + irinotecan) as
second-line chemotherapy, IRIS regimen was superior to
the FOLFIRI regimen for mCRC patients who previously
received an oxaliplatin-based regimen [20]. This difference
was explained by the fact that patients previously treated
Table 2 Toxicity (n = 31)
Number of patients, n (%)
Grade 1 Grade 2 Grade 3 Grade 4 All grades Grade 3/4
Hematological adverse events
Anemia 4 4 2 0 10 (32) 2 (6)
Thrombocytopenia 7 1 0 0 8 (26) 0 (0)
Neutropenia 4 1 1 0 6 (19) 1 (3)
Febrile neutropenia – – 1 0 1 (3) 1 (3)
Non-hematological adverse events
Stomatitis 7 8 8 0 23 (74) 8 (26)
Fatigue 13 10 0 – 23 (74) 0 (0)
Anorexia 10 9 2 0 21 (68) 2 (6)
Diarrhea 8 4 3 0 15 (48) 3 (10)
Skin pigmentation 8 4 0 0 12 (39) 0 (0)
Hypertension 7 2 1 0 10 (32) 1 (3)
Nausea 8 1 0 – 9 (29) 0 (0)
Epistaxis 9 0 0 0 9 (29) 0 (0)
Watering eyes 4 1 0 – 5 (16) 0 (0)
Vomiting 3 1 0 0 4 (13) 0 (0)
The most common toxicities of all grade were stomatitis (74 %), fatigue (74 %), anorexia (68 %) and diarrhea (48 %)
The major grade 3–4 toxicities were stomatitis (26 %) and diarrhea (10 %)
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with an oxaliplatin-containing regimen had a higher level
of DPD gene expression in the tumor tissue than those
not treated with oxaliplatin, and this mechanism was
related to the stronger effects of S-1 [21].
In the present study, the enhancement made in the
treatment regimen for refractory mCRC was the S-1/LV
combination therapy. The addition of LV enhanced the
anti-tumor activity of S-1 by TS inhibition. Compared
with S-1 monotherapy for previously untreated mCRC, S-
1/LV combination therapy demonstrated an improvement
in objective response rate from 35 to 57 % and improve-
ment in time to progression from 5.3 to 6.7 months [8].
Moreover, it is reported that acquisition of resistance to
5FU is related to increased TS expression. 5FU-resistant
cell lines show increased TS mRNA expression, protein
expression, and activity compared with their respective
parent cells in in vitro and in vivo assays [22, 23]. On the
basis of this finding, concurrent treatment with LV may
have contributed in overcoming resistance to 5FU and
yielded some efficacy in the present study.
Little comparative data are available regarding the activ-
ity of Bev after second-line therapy. Bev therapy in the
later-line setting has been reported in several phase-II
studies and in retrospective series [24–29]. According to
these reports, Bev does not show a tendency for reduction
in tumour size but results in tumour stabilisation and
improved survival. However, studies evaluating its effect
in later-line treatment of Bev re-introduction are limited.
Recently, international multicentre study (ML18147 study)
revealed that continuation of Bev after initial tumour
progression significantly improved PFS and OS [12].
Similar result was also observed in an Italian multicentre
study (BEBYP study), which demonstrated a significant
improvement in PFS and OS continuing Bev plus second-
line chemotherapy [13]. These results imply disease may
still partially depend on VEGF after disease progression
and raises the possibility that the angiogenic signal may
continue throughout the tumor lifespan. With this specu-
lation, Bev re-introduction may still contribute to enhance
anti-tumour activity that has already proved to be resist-
ant. Although we must note that prospective and random-
ized clinical trials are lacking regarding the role of Bev in
chemo-refractory mCRC patients, we could speculate that
a combination with Bev provides some efficacy in a heavily
treated population.
With regard to the difference in patients in KRAS muta-
tion status in this study, no significant difference was
observed in either disease stabilization or survival benefit
between KRAS mutation status. Another finding in this
study which is noteworthy, is 1 patient who had BRAF
mutation achieved PR. BRAF mutation is associated with
poor prognosis because of more aggressive and rapidly
progressing disease and is also predictive of a lack of
response to chemotherapy in mCRC. However, in this
patient, the size of hepatic metastases remarkably decreased
after resistance to all standard chemotherapies. This fact
suggests that in patients with BRAF mutation, SL/Bev may
have potent anti-tumour activity based on some specific
effects. A possible explanation for this is the role played by
γ-glutamyl hydrolase (GGH) in regulating intracellular
folate levels. Low GGH expression is associated with higher
folate levels, leading to the enhancement of anti-tumor
activity in 5-FU with LV [30]. In the BRAF-mutated onco-
gene, the CpG island methylator phenotype (CIMP+) fre-
quently occurs within gene promoter regions, and CIMP+
is associated with low GGH expression. For this reason, SL/
Bev may be more effective in BRAF-mutant patients than
in BRAF-wild-type ones. Although this phenomenon may
have occurred by chance, it remains noteworthy.
This study has some limitations. One is that it is a single-
arm study design with no control group for comparison.
Therefore, we cannot rule out some potential bias, such as
the selection of patients with good prognosis. In fact, a
majority of patients except two in our study (94 %) had an
ECOG PS status of <2. The second limitation is it is unclear
whether the efficacy and safety of S-1 in Japanese patients
would be similar to those in Western patients. Despite
these limitations above, SL/Bev may provide an additional
advantage. This regimen considers that no cross-resistance
to new anti-cancer agents for refractory mCRC, such as
regorafenib and TAS102, exists. Therefore, SL/Bev may
provide a therapeutic option even after failure with these
agents. To confirm its efficacy, further prospective random-
ized control trial is necessary to compare SL/Bev with BSC
in patient with refractory mCRC.
Conclusions
In conclusion, SL/Bev showed promising activity in heav-
ily pre-treated patients with mCRC who showed failure of
5-FU, oxaliplatin, irinotecan, Bev and anti-EGFR antibody
treatment. A further randomized control trial will be
needed to fully evaluate the usefulness of these current
findings.
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